Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 382

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 382
---
 Inc., as well as other commercial and academic laboratories. Further, we face competition from new entrants in the market for genetic screening, including informatics and analysis pipeline developers as well as focused, integrated providers of genetic tools and services for health and wellness, including Illumina, which is also one of our suppliers. In addition to the companies that currently offer traditional genetic testing services and research centers, other established and emerging healthcare, information technology and service companies may commercialize competitive products including informatics, analysis, integrated genetic tools and services for health and wellness. We believe that we are uniquely positioned to compete based on several key competitive factors: • Geographic focus on Latin America: our operations are focused on Latin America, leveraging our extensive knowledge of the local regulatory environment, languages, and cultural context. We have developed 9+ years of operational expertise and a strong network of partner laboratories across Latin America, four of which are investors in OmnigenicsAI. This network facilitates rapid and efficient market entry, providing regional labs with localized end -to -endsolutions adapted to market needs without requiring additional investments from partners. • Comprehensive Insights, Precision and Actionable Results: we have accumulated over 114 terabytes of genomic data specific to the Latin American population, one of the most underrepresented groups in global databases. This unique data enables us to deliver more accurate and region -specificinsights. In addition, our tests are designed to provide actionable results that combine genetic, microbiome, epigenetic, and lifestyle data, supporting a more comprehensive, data -drivenapproach to health and wellness. • Localized, Efficient and Accessible Solutions: we prioritize low -cost, high -qualitysolutions, with optimized turnaround times that will be made possible by our wet -labsand streamlined logistics network. This approach enables us to deliver results efficiently and make our services accessible to a wider audience, distinguishing us in a market often dominated by more costly and less regionally adapted services. For example, our products and services will be built on localized genomic datasets, while our results and client services will be provided in Spanish, meeting the specific cultural needs of each market. 191 • Data -Driven Approach and AI Integration: we are building a proprietary, omni -modaldata lake that integrates genomic, microbiome, and lifestyle data. This robust data foundation will fuel our AI capabilities, allowing us to offer precision -basedhealth management and prevention tools specifically tailored to the Latin American population. As AI and next -generationDNA sequencing costs decrease, we are well -positionedto